New Zealand markets open in 2 hours 41 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
31.26+0.87 (+2.86%)
As of 03:18PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.16B
Enterprise value 2.75B
Trailing P/E 28.94
Forward P/E 42.55
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.41
Price/book (mrq)5.78
Enterprise value/revenue 5.26
Enterprise value/EBITDA 22.27

Trading information

Stock price history

Beta (5Y monthly) 0.46
52-week change 341.74%
S&P500 52-week change 324.96%
52-week high 335.22
52-week low 320.84
50-day moving average 327.64
200-day moving average 326.59

Share statistics

Avg vol (3-month) 31.16M
Avg vol (10-day) 31.3M
Shares outstanding 5104.11M
Implied shares outstanding 6104.11M
Float 884.99M
% held by insiders 111.39%
% held by institutions 191.97%
Shares short (31 May 2024) 419.29M
Short ratio (31 May 2024) 415.25
Short % of float (31 May 2024) 426.08%
Short % of shares outstanding (31 May 2024) 418.53%
Shares short (prior month 30 Apr 2024) 419.8M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 22.54%
Operating margin (ttm)20.09%

Management effectiveness

Return on assets (ttm)11.96%
Return on equity (ttm)21.91%

Income statement

Revenue (ttm)523.53M
Revenue per share (ttm)5.12
Quarterly revenue growth (yoy)39.00%
Gross profit (ttm)N/A
EBITDA 122.8M
Net income avi to common (ttm)117.2M
Diluted EPS (ttm)1.05
Quarterly earnings growth (yoy)74.80%

Balance sheet

Total cash (mrq)410.76M
Total cash per share (mrq)3.94
Total debt (mrq)76k
Total debt/equity (mrq)0.01%
Current ratio (mrq)5.18
Book value per share (mrq)5.27

Cash flow statement

Operating cash flow (ttm)124.84M
Levered free cash flow (ttm)123.86M